TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12197983

Group type: EXPERIMENTAL
Intervention: Intervention (written recommendations, technical assistance, and worker training)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Comparison (written recommendations alone)
Number of subjects: 48
Study: 9527206

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no ischemic preconditioning)
Number of subjects: 70
Study: 7630075

Group type: EXPERIMENTAL
Intervention: Enteral catheter feeding using Inpitan, ovolact, and hypernutril administered via the nasal passage into the proximal segment of the jejunum starting 5 to 7 days after the operation.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Parenteral feeding (Control group).
Number of subjects: 60
Study: 2294793

Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg every 6 hours)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 31875737

Group type: EXPERIMENTAL
Intervention: Immediate cord clamping (ICC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Delayed cord clamping (DCC)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (ICC and DCC)
Number of subjects: 38
Study: 30468636

Group type: EXPERIMENTAL
Intervention: 3D printed models
Number of subjects: 2

Group type: COMPARATOR
Intervention: MRI images
Number of subjects: 2
Study: 29188854

Group type: EXPERIMENTAL
Intervention: Combination of nutraceuticals based on Bacopa monnieri, L‐theanine, Crocus sativus, copper, folate and vitamins of B and D group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25716777

Group type: EXPERIMENTAL
Intervention: DM60 (60mg/day dextromethorphan)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: DM120 (120mg/day dextromethorphan)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 23475700

Group type: EXPERIMENTAL
Intervention: Impaired relaxation (LV-IR), n = 15
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pseudonormal or restrictive (LV-P/R), n = 15
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Normal function (LV-NF), n = 15
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (N), n = 14
Number of subjects: 45
Study: 21425510

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (cFNB) with ropivacaine 0.2% from surgery until the following morning, then continued with perineural ropivacaine for 4 days (n=28)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normal saline (control group, n=26)
Number of subjects: 54
Study: 18774567

Group type: EXPERIMENTAL
Intervention: 400 microg sublingual misoprostol
Number of subjects: 105

Group type: COMPARATOR
Intervention: Manual vacuum aspiration (control)
Number of subjects: 105
Study: 17239711

Group type: EXPERIMENTAL
Intervention: Intravenous insulin infusion
Number of subjects: 76

Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 76
Study: 14633525

Group type: EXPERIMENTAL
Intervention: Ringer's acetate solution (25 mL/kg, mean 1565 mL) infused over 15, 30, 45, and 80 min
Number of subjects: 5
Study: 10708287

Group type: EXPERIMENTAL
Intervention: Abacavir monotherapy (100, 300 or 600 mg twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine/zidovudine combination therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Abacavir monotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Abacavir with mutations
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Abacavir with single mutations
Number of subjects: 60
Study: 9083598

Group type: EXPERIMENTAL
Intervention: Existing curriculum plus the intervention curriculum
Number of subjects: 1657

Group type: COMPARATOR
Intervention: Existing curriculum
Number of subjects: 1657
Study: 8415473

Group type: EXPERIMENTAL
Intervention: Tianeptine (T) 37.5 mg/day
Number of subjects: 83

Group type: COMPARATOR
Intervention: Maprotiline (M) 75 mg/day
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tianeptine (T) with Hormone Replacement Therapy (HRT)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tianeptine (T)
Number of subjects: 83
Study: 3533086

Group type: EXPERIMENTAL
Intervention: Suprofen syrup 200 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metamizole syrup 500 mg
Number of subjects: 60
Study: 30397963

Group type: EXPERIMENTAL
Intervention: Disaster educational program for nursing students
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 30134772

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI) - SC PMTCT plus the 'Protect Your Family' intervention; 6 CHCs; n = 342
Number of subjects: 699

Group type: COMPARATOR
Intervention: Standard Care (SC) - Standard Care condition plus time-equivalent attention-control on disease prevention; 6 CHCs; n = 357
Number of subjects: 699
Study: 27058233

Group type: EXPERIMENTAL
Intervention: Extended adjuvant letrozole
Number of subjects: 0
Study: 24638119

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) intervention to encourage CRC screening (n=10,000)
Number of subjects: 13279

Group type: COMPARATOR
Intervention: Usual care (n=3279)
Number of subjects: 13279

Group type: EXPERIMENTAL
Intervention: IVR intervention
Number of subjects: 13279
Study: 21757401

Group type: EXPERIMENTAL
Intervention: Pramipexole treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 25
Study: 19637794

Group type: EXPERIMENTAL
Intervention: Continuous infusion of meropenem (1.0 g/day over 24 hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intermittent infusion of meropenem (0.5 g infused morning and evening)
Number of subjects: 100
Study: 17882870

Group type: EXPERIMENTAL
Intervention: Fresh allogenic joints (Group A, n=7)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Frozen allogenic joints (Group B, n=6)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Immunological examination (Group A vs Group B)
Number of subjects: 13
Study: 15724756

Group type: EXPERIMENTAL
Intervention: 6.0% hydrogen peroxide (Crest Whitestrips)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6.5% hydrogen peroxide (Crest Professional Whitestrips)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide (Day White Excel 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 9.5% hydrogen peroxide (Day White Excel 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (Opalescence)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 60
Study: 12466771

Group type: EXPERIMENTAL
Intervention: Manipulative treatment of the structures of the shoulder girdle in addition to standard treatment by the general practitioner
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard treatment by the general practitioner
Number of subjects: 250
Study: 10451015

Group type: EXPERIMENTAL
Intervention: Truth group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Malinger group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 10159676

Group type: EXPERIMENTAL
Intervention: Office-based intervention using touchscreen computer assessment, goal setting, and problem-solving assistance
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Follow-up components including phone calls and videotape or interactive video instruction
Number of subjects: 95
Study: 2140281

Group type: EXPERIMENTAL
Intervention: 5FU monochemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polychemotherapy protocols (FAM and SMF)
Number of subjects: 0
Study: 356523

Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31937528

Group type: EXPERIMENTAL
Intervention: Peer-delivered diabetes self-management program integrating CBT principles
Number of subjects: 195

Group type: COMPARATOR
Intervention: Peer-delivered general health advice program
Number of subjects: 195
Study: 31303190

Group type: EXPERIMENTAL
Intervention: 12-week intervention promoting healthier beverages (water, unsweetened low- or non-fat milk)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (delayed-intervention)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 12-week intervention promoting healthier beverages
Number of subjects: 154
Study: 26825280

Group type: EXPERIMENTAL
Intervention: Autorefraction preoperatively
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Autorefraction postoperatively
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Subjective refraction preoperatively
Number of subjects: 27
Study: 26251920

Group type: EXPERIMENTAL
Intervention: 3 g fish oil/day (540 mg EPA + 360 mg DHA)
Number of subjects: 83

Group type: COMPARATOR
Intervention: 3 g soy oil/day (placebo)
Number of subjects: 83
Study: 23433768

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/day
Number of subjects: 164

Group type: COMPARATOR
Intervention: Pravastatin 20 mg/day
Number of subjects: 164
Study: 21153806

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19659504

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg + Amlodipine 5 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Olmesartan medoxomil 20 mg alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg + Atenolol 50 mg
Number of subjects: 18
Study: 17496229

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Not receiving HBO2
Number of subjects: 238
Study: 15150666

Group type: EXPERIMENTAL
Intervention: Fixed-flexion radiography with a specially designed frame (SynaFlexer)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Automated analysis of JSW measurements
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Repeat knee radiographs using automated analysis
Number of subjects: 165
Study: 11314888

Group type: EXPERIMENTAL
Intervention: Oscillating rotating electric toothbrush (slower head speed)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oscillating rotating electric toothbrush (faster head speed)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 16

Group type: COMPARATOR
Intervention: Toothpaste slurry (3 g/10 ml water)
Number of subjects: 16
Study: 9072571

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (2,000 rad) followed by cystectomy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 140
Study: 8202902

Group type: EXPERIMENTAL
Intervention: Theophylline (sustained release preparation, orally, adjusted to achieve blood level above 55.5 mumol/l)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 6611576

Group type: EXPERIMENTAL
Intervention: High frequency transcutaneous electrical nerve stimulation (TNS)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Acupuncture-like transcutaneous electrical nerve stimulation (TNS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo TNS
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Grip strength measurements
Number of subjects: 33
Study: 31464354

Group type: EXPERIMENTAL
Intervention: Swallowing speed for water (measured at 90 mL)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Swallowing speed <10 mL/s
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Optimized cutoff value for detection of aspiration
Number of subjects: 115
Study: 29161684

Group type: EXPERIMENTAL
Intervention: Higher intensity CRRT (effluent flow 40 mL/kg/h)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Lower intensity CRRT (effluent flow 25 mL/kg/h)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Higher intensity CRRT
Number of subjects: 444
Study: 27887653

Group type: EXPERIMENTAL
Intervention: Intravascular cooling
Number of subjects: 934

Group type: COMPARATOR
Intervention: Surface cooling
Number of subjects: 934
Study: 24267270

Group type: EXPERIMENTAL
Intervention: Untreaded shoes
Number of subjects: 18

Group type: COMPARATOR
Intervention: Treaded shoes
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Shoe/floor design
Number of subjects: 18
Study: 22512470

Group type: EXPERIMENTAL
Intervention: Bottom‐up training including activities focused on auditory perception, discrimination, and phonological awareness
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Top‐down training including a range of language activities
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Personal FM systems
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study: 20796146

Group type: EXPERIMENTAL
Intervention: PegIFN alfa‐2b
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional IFN alfa‐2b
Number of subjects: 58

Group type: COMPARATOR
Intervention: Non-HBeAg seroconversion
Number of subjects: 58
Study: 17696230

Group type: EXPERIMENTAL
Intervention: HD-03/ES (two capsules twice daily for six months)
Number of subjects: 25
Study: 17239273

Group type: EXPERIMENTAL
Intervention: Parenteral estrogen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional androgen deprivation therapy (ADT)
Number of subjects: 0
Study: 15133780

Group type: EXPERIMENTAL
Intervention: New therapy during open-label follow-up phase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11026856

Group type: EXPERIMENTAL
Intervention: Breath-hold cine MRI with stereological analysis
Number of subjects: 11
Study: 8872767

Group type: EXPERIMENTAL
Intervention: Daily consecutive administration of 9 million units (MU) IFN‐alpha for 2 weeks and thereafter 3 MU intermittently 3 times weekly for 22 weeks (Group A)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Exclusively intermittent administration; 9 MU IFN‐alpha twice weekly or 6 MU IFN‐alpha thrice weekly for 24 weeks (Group B)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 81
Study: 1510045

Group type: EXPERIMENTAL
Intervention: Metal brackets
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Silkon brackets
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Transcend 2000 brackets
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Debonded Transcend 2000 brackets
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Debonded silanized Transcend 2000 brackets
Number of subjects: 75
Study: 6239689

Group type: EXPERIMENTAL
Intervention: Prednisolone at a dose of 5 mg twice a day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tamoxifen at a dose of 10 mg twice a day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tamoxifen with additional prednisolone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no prednisolone)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Overall treatment response
Number of subjects: 33
Study: 29983128

Group type: EXPERIMENTAL
Intervention: Individual Mindfulness Program for Voices (iMPV)
Number of subjects: 14
Study: 27095187

Group type: EXPERIMENTAL
Intervention: Learned Helplessness (LH) measured by the Rheumatology Attitude Index (RAI)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Self-Efficacy (SE) measured by the Arthritis Self-efficacy Scale (ASES)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Disease Activity measured by the Clinical Disease Activity Index (CDAI)
Number of subjects: 115
Study: 25920500

Group type: EXPERIMENTAL
Intervention: Budesonide MMX 9 mg as monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide MMX 9 mg as add-on therapy to 5-ASAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide MMX 9 mg monotherapy in CORE I study extension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Budesonide MMX 9 mg
Number of subjects: 0
Study: 23973954

Group type: EXPERIMENTAL
Intervention: Nonapical RV lead location (n=86)
Number of subjects: 742

Group type: COMPARATOR
Intervention: Apical RV lead location (n=656)
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Nonapical RV lead location
Number of subjects: 742

Group type: COMPARATOR
Intervention: Apical RV lead location
Number of subjects: 742
Study: 21356040

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 19515739

Group type: EXPERIMENTAL
Intervention: Active diet intervention (increase in n-3 intake and decrease in n-6 intake)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Control diet intervention
Number of subjects: 616
Study: 16752263

Group type: EXPERIMENTAL
Intervention: 25 microg vaginal tablets of misoprostol
Number of subjects: 120

Group type: COMPARATOR
Intervention: One-eighth of a 200-microg oral tablet administered intravaginally
Number of subjects: 120
Study: 15701186

Group type: EXPERIMENTAL
Intervention: Three monthly subcutaneous injections of 3.6 mg of goserelin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Single subcutaneous injection of 10.8 mg of goserelin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 11417282

Group type: EXPERIMENTAL
Intervention: Double gloves with indicator
Number of subjects: 200

Group type: COMPARATOR
Intervention: Single gloves
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 200
Study: 9267920

Group type: EXPERIMENTAL
Intervention: Limited microbiological investigation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Full microbiological investigation
Number of subjects: 40
Study: 3527029

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meglumine iothalamate
Number of subjects: 0
Study: 30306229

Group type: EXPERIMENTAL
Intervention: 12 mg E2-valerate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 27496252

Group type: COMPARATOR
Intervention: Conventional implants (control group, Ø3.3‐3.7mm, L11‐13mm)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Mini implants (study group, Ø1.8‐2.4mm, L13‐15mm)
Number of subjects: 26
Study: 25287156

Group type: EXPERIMENTAL
Intervention: Proteinuria present (P/C ratio >23 mg/mmol)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No proteinuria (P/C ratio ≤23 mg/mmol)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Proteinuria
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: P/C ratio
Number of subjects: 64
Study: 22929636

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clonidine 150 mcg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 20063135

Group type: EXPERIMENTAL
Intervention: Remifentanil 1.32 microg.kg(‐1) co-administered with propofol 2.5 mg.kg(‐1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Remifentanil doses of 0.25, 0.5, 1, or 2 microg.kg(‐1)
Number of subjects: 68
Study: 17900324

Group type: EXPERIMENTAL
Intervention: Basket group (N = 30)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Brush group (N = 26)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Basket group (N = 30) with presampling balloon dilation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Brush group (N = 26) with presampling balloon dilation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 56
Study: 15986946

Group type: EXPERIMENTAL
Intervention: Beautifil (for cervical restorations)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Reactmer (for cervical restorations)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Beautifil (for occlusal restorations)
Number of subjects: 15
Study: 15515566

Group type: EXPERIMENTAL
Intervention: Curettement-adhesive group (42 cases)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (41 cases) - treated with Vaseline gauze packing
Number of subjects: 83
Study: 9430541

Group type: EXPERIMENTAL
Intervention: 2% dorzolamide drops
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 19
Study: 8624292

Group type: EXPERIMENTAL
Intervention: Fixed treatment (FT) - 4 full MOPP/ABVD courses
Number of subjects: 88

Group type: COMPARATOR
Intervention: Individual treatment (IT) - treatment up to complete remission (CR)
Number of subjects: 88
Study: 2768664

Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo analgesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonhypnotic suggestion for analgesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive coping
Number of subjects: 0
Study: 781226

Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium (FC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30770766

Group type: EXPERIMENTAL
Intervention: Catheter removal on postoperative day 2
Number of subjects: 220

Group type: COMPARATOR
Intervention: Catheter removal on postoperative day 7
Number of subjects: 220
Study: 28549620

Group type: EXPERIMENTAL
Intervention: Opioid prescribing guidelines implemented in April 2012
Number of subjects: 0
Study: 25301892

Group type: EXPERIMENTAL
Intervention: Preoperative template obtained for review at the time of ORIF (group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contralateral radiograph obtained after surgery (group 2)
Number of subjects: 0
Study: 22868657

Group type: EXPERIMENTAL
Intervention: raloxifene hydrochloride 60 mg/day
Number of subjects: 144

Group type: COMPARATOR
Intervention: alfacalcidol 1 μg/day
Number of subjects: 144

Group type: COMPARATOR
Intervention: no medication
Number of subjects: 144
Study: 21575502

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine group (large dose compound Sophora flavescens Ait injection, 20 ml/d, 21 days as a cycle)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Chemotherapy group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine group
Number of subjects: 96
Study: 19565554

Group type: EXPERIMENTAL
Intervention: Intervention Tool Kit (n = 458)
Number of subjects: 921

Group type: COMPARATOR
Intervention: Wait-list control (n = 463)
Number of subjects: 921
Study: 16784623

Group type: EXPERIMENTAL
Intervention: Minimally invasive THA with anterior incision (Group 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: THA with standard posterolateral incision (Group 2)
Number of subjects: 120
Study: 15301774

Group type: EXPERIMENTAL
Intervention: Isokinetic muscle actions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isometric muscle actions
Number of subjects: 10